Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

Amgen and Novartis partner with biotech venture capital firm

Atlas Venture fund aims to create 15 new biotech companies

Novartis building

Novartis gets FDA green light for new Ilaris indication

Immunotherapeutic wins US approval for severe form of childhood arthritis

- PMLiVE

Global biosimilars market to reach $2.45bn in 2013

And EMA plans to revise its guidelines for the area

- PMLiVE

Arena pulls obesity drug Belviq application in EU

EMA asks for more data

- PMLiVE

Teva appoints chief strategy officer

Paul Sekhri has experience at Novartis, Ariad and TPG Biotech

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

Novartis building

Novartis hit by kickback lawsuits in US

Company accused of paying millions of dollars to doctors in exchange for prescribing drugs

- PMLiVE

EMA refuses to back Pfizer’s Xeljanz in rheumatoid arthritis

Surprise after approvals in US and Japan

Novartis building

NICE turns down Novartis’ blood cancer drug Jakavi

Uncertainties remain about drug’s cost-effectiveness, according to final draft guidance

Novartis day

Xolair gets asthma green light from NICE

Final guidance recommends Novartis drug for severe persistent asthma 

- PMLiVE

Alkermes cuts jobs in Ireland as Novartis invests

130 jobs to go at manufacturing facility in Athlone as Novartis creates 100 roles in Dublin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links